Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.56 |
| ▸ | MMP9 | P14780 | 3/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.56 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491474 | 1.00 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL4832393 | 0.88 | MMP9 (0.68) | MMP2MMP9KMT2ACA2CA12 | |
| SCHEMBL10102615 | 0.85 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL2053891 | 0.85 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL7025505 | 0.83 | GFER (0.54) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL6610112 | 0.82 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL6923978 | 0.82 | CA2 (0.59) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL31477053 | 0.81 | MMP9 (0.69) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL1000596 | 0.81 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL2161085 | 0.81 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289810-A1 | Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments | MAM-AGE S.R.L. (IT) | 2025-09-18 | — | — | US | disclosed |
| WO-2023209109-A1 | COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND THEIR USE AS MEDICAMENTS | MAM - AGE S.R.L. (IT) | 2023-11-02 | — | — | WO | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | SLC1A3 3986/4885SLC1A2 4025/4885SLC1A1 3841/4885 |
| US-20250289810-A1 | Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments | NLRP3, NLRP1, IL18 | SLC1A3 655/4885SLC1A2 1375/4885SLC1A1 614/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | SLC1A3 1775/4885SLC1A2 2631/4885SLC1A1 1489/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | SLC1A3 2843/4885SLC1A2 3524/4885SLC1A1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.